AOD-9604

Not FDA-approved. Research dosages typically range from 250-500 mcg/day via subcutaneous injection, with 300-500 mcg/day being the most commonly cited. Phase II trials used up to 1 mg/day. Cycles often run 4-12 weeks. Over 900 participants across six controlled trials established tolerability.

Activates beta-3 adrenergic receptors in adipose tissue, triggering the release of stored fatty acids for energy use and enhancing fat oxidation.

Reduces accumulation of new fat in adipocytes by inhibiting de novo lipogenesis, working to prevent new fat storage while mobilizing existing fat stores.

Mimics the lipolytic fragment of growth hormone without activating the GH receptor, meaning no IGF-1 elevation, no blood sugar disruption, no water retention, and no cell proliferation effects.

Modulates pro-inflammatory cytokines including TNF-alpha, IL-6, and matrix metalloproteinases (MMPs), which play central roles in cartilage degradation.

Preferentially mobilizes stored lipids from obese fat cells, stimulating fat oxidation. Phase II clinical trials in humans showed dose-dependent fat reduction.

Preclinical studies in rabbit osteoarthritis models showed enhanced cartilage regeneration with intra-articular injections, particularly when combined with hyaluronic acid.

Confirmed across six human trials: AOD-9604 does not elevate IGF-1, disrupt blood sugar, cause water retention, or promote cell proliferation, offering a favorable safety profile.

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, g...

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · Omar F Rahman, Steven J Lee, William A Seeds

Numerous drugs with potent toxicity against cancer cells are available for treating malignancies, bu...

Drug design, development and therapy · Mahmoud M Habibullah, Syam Mohan, Nabeel Kashan Syed, Hafiz ...

Since the installation of anti-doping rules and regulations and their international enforcement in t...

Mass spectrometry reviews · Wilhelm Schänzer, Mario Thevis

The analysis of low-molecular-mass peptides in doping controls has become a mandatory aspect in spor...

Journal of separation science · Andreas Thomas, Christian Görgens, Sven Guddat, Detlef Thiem...

AOD9604 is a peptide consisting of the C-terminal fragment of human growth hormone from amino acids ...

Drug testing and analysis · Holly D Cox, Stacy J Smeal, Cole M Hughes, James E Cox, Dani...